O-Phosphoethanolamine
|
Basic information |
| Metabolite name | O-Phosphoethanolamine |
 | HMDB0000224 |
 |
C00346 |
 |
1015 |
| Synonyms | 2-Aminoethyl dihydrogen phosphate; |
| No. of studies | 26 |
|
Basic information |
| Metabolite name | O-Phosphoethanolamine |
| HMDB0000224 |
|
C00346 |
|
1015 |
| Synonyms | 2-Aminoethyl dihydrogen phosphate; |
| No. of studies | 26 |
|
Relationship between O-Phosphoethanolamine and depression (count: 26) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M082 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M082 | Type3 | medium dose of DG group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M1056 | Type1 | maternal separation group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Prefrontal cortex | Cynomolgus monkey | Down |
| Study M1090 | Type2 | CUMS + hyperbaric oxygen treatment group vs. CUMS group | Plasma | BALb/c mouse | Up |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M116 | Type3 | LY group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | CRS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Up |
| Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M313 | Type1 | depression group vs. control group | Medial frontal cortex | Human | Up |
| Study M458 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Down |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M578 | Type1 | restraint stress offspring group vs. control offspring group | Hippocampus | Sprague-Dawley rat | Up |
| Study M613 | Type2 | CSDS susceptible + imipramine group vs. CSDS + vehicle group | Ventral hippocampus | C57BL/6 J mouse | Down |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Down |
| Study M770 | Type4 | responder group vs. non-responder group | Serum | C57BL/6 mouse | Up |
| Study M800 | Type3 | fluoxetine group vs. control group | Prelimbic cortex | Rhesus monkey | Down |
| Study M849 | Type1 | CUMS group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M883 | Type1 | MDD group vs. control group | Blood | Human | Up |